Treatment of Myasthenia Gravis Exacerbation or Crisis With Efgartigimod

计划入组 20 人 · 首次发布于 2025 年 3 月 6 日

Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis

计划入组 16 人 · 首次发布于 2024 年 11 月 14 日

A Prospective Cohort Study Of Myasthenia Gravis

计划入组 200 人 · 首次发布于 2020 年 12 月 19 日

ThRabis

PRAXIS-040

PRAXIS-030

ORASIS PHARMACEUTICALS LTD

Israel

Orasis Pharmaceuticals Ltd.

Israel

Travis County Healthcare District

United States

FutureChem Receives Korean Approval for ProstaView Prostate Cancer Diagnostic, Marking Second Global PSMA-PET Agent

Orasis Pharmaceuticals Expands Qlosi Access with New Starter Packs Following Strong Market Adoption

Orasis Pharmaceuticals Prepares for March Launch of FDA-Approved Presbyopia Eye Drop Qlosi